1955. Cortisone

RCT/Cortisone/ASUC/ Induction

Cortisone in ulcerative colitis final report on a clinical trial

Placebo-controlled trial.

Patients with ASUC hospitalized were randomized to cortisone vs placebo.

Cortisone doses: 100mg/d for 6 weeks vs 100mg/d for 2-3 weeks followed by 50-75mg/day; doses >100mg; therapy <6 weeks. Sulphasalazine, antibiotics and rectal instillations at discretion of clinician.


<u>Primary endpoints:</u> Clinical response.

Results: N=210

- Short-term clinical remission: 41.3% cortisone vs 15.8% placebo, p<0.01
- Short-term clinical response: 70% cortisone vs 40% placebo, p<0.01
- Response was better in first attacks as compared to relapses.
- Long-term (follow-up 9 months) first attacks: dead 7% cortisone vs 23.7% placebo p<0.02; alive with symptoms 44.2% cortisone vs 55.3% placebo p<0.02; symptom free 48.8% cortisone vs 21.1% placebo, p<0.02

Conclusion:

At every stage of severity of UC and in both first attacks and relapses, cortisone was better than placebo.



J